



SIVEXTRO® (tedizolid phosphate) PA CRITERIA:

FDA approved uses for Sivextro:

Acute bacterial skin and skin structure infections (ABSSSI) - Caused by susceptible isolates of the Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.

Diagnosis: ☐ Acute bacterial skin and skin structure infections (ABSSSI) ICD-10 code(s): Authorization Criteria: Requests for Sivextro (tedizolid phosphate) may be approved if ALL the following criteria are met:			
		□ Yes □ No	Age \geq 18 years AND
		□ Yes □ No	Prescriber is or has consulted with an infectious disease specialist AND
□ Yes □ No	FDA approved indication AND		
□ Yes □ No	Culture and sensitivity report (dated within past 7 days) confirms the isolated organism is susceptible AND		
□ Yes □ No	Treatment failure, intolerance, and/or contraindication to other antibiotics to which organism is susceptible		

Additional information to consider:

When applicable, continuation of therapy when individual is transitioning intravenous therapy to oral therapy to facilitate a hospital discharge

Quantity limit: 6 tablets